ADAM GUDE: Open Payments
NPI 1225482524 · BENNETTSVILLE, SC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,629 in 87 payments from 19 companies in 2025. Trend: 2023 $630 · 2024 $1,001 · 2025 $1,629
Food & beverage: $1,629
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 17 | $350 |
| Novo Nordisk Inc | 11 | $222 |
| AstraZeneca Pharmaceuticals LP | 11 | $173 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $156 |
| Merck Sharp & Dohme LLC | 9 | $140 |
| GlaxoSmithKline, LLC. | 6 | $107 |
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $88 |
| Corcept Therapeutics | 4 | $77 |
| Insulet Corporation | 2 | $46 |
| Exact Sciences Corporation | 2 | $40 |
Products named: VRAYLAR, CAPLYTA, VERQUVO, TRELEGY ELLIPTA, Ozempic, Kerendia, AIRSUPRA, Korlym.
Industry payments across SC — which companies pay providers there.
